Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (24411)	8/12/1998 1:05:00 PM
From: Machaon	Respond to of 32384

<< otoh, read the latest Lehman report on VICL where they talk about the technical reasons why that stock dropped. >> Thanks for bringing up this article! It was very interesting reading. Lehman wrote that Vical's price could have suffered a sharp fall in price, partly because of the mishandling of 150,000 in sales by a large institutional trader (big boy). The overhand in LGND is much greater than that! << pretty good insights that may be applicable to LGND as well. >> Do we really want to restrict this thread and not discuss the impact of the institutional traders? I think that you are right about the article being applicable to LGND. The negative pressures on LGND, and many other biotechs, regardless of pipeline news and results, may be better understood by what the "big boys" are doing, compared to retail trading. Today's low volume is a disappointment. Good luck, Bob